Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AEZS Stock Forecast 2026-2027
$3.73
Current Price
$17.51M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AEZS Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AEZS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-60.0%
From 52W High of $9.32
+2,385.3%
From 52W Low of $0.15
📊 TOP ANALYST CALLS
Did AEZS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aeterna Zentaris is one of their latest high-conviction picks.
Latest AEZS Stock Price Targets & Analyst Predictions
AEZS has shown a year-to-date change of 0.0% and a 1-year change of 0.0%, reflecting flat performance over the past year. Comprehensive analyst forecasts are currently unavailable for AEZS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AEZS Analyst Ratings
2
Buy
0
Hold
0
Sell
AEZS Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.73
Latest AEZS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AEZS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Jul 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 30, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $1.50 |
| Oct 25, 2021 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $2.00 |
| Nov 9, 2015 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| Apr 14, 2015 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Upgrade | $1.25 |
| Jul 17, 2014 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $3.00 |
| Jul 25, 2013 | Euro Pacific Capital | Hold | Initiates | $N/A | |
| Jan 3, 2013 | McNicoll Lewis Vlak | Buy | Upgrade | $N/A | |
| Dec 31, 2012 | Canaccord Genuity | Hold | Maintains | $2.50 | |
| Oct 12, 2012 | Bloom Burton & Co. | Sell | Maintains | $2.00 | |
| Apr 2, 2012 | Oppenheimer | Perform | Downgrade | $N/A |
Aeterna Zentaris Inc. (AEZS) Competitors
The following stocks are similar to Aeterna Zentaris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aeterna Zentaris Inc. (AEZS) Financial Data
Aeterna Zentaris Inc. has a market capitalization of $17.51M with a P/E ratio of -1.9x. The company generates $2.37M in trailing twelve-month revenue with a 41.1% profit margin.
Revenue growth is -99.8% quarter-over-quarter, while maintaining an operating margin of -152,750.0% and return on equity of -81.7%.
Valuation Metrics
Market Cap
$17.51M
Enterprise Value
$-21,857,230
P/E Ratio
-1.9x
PEG Ratio
-1.7x
Price/Sales
7.4x
Growth & Margins
Revenue Growth (YoY)
-99.8%
Gross Margin
+35.0%
Operating Margin
-152,750.0%
Net Margin
+41.1%
EPS Growth
+129.9%
Financial Health
Cash/Price Ratio
+652.9%
Current Ratio
5.9x
Debt/Equity
1.8x
ROE
-81.7%
ROA
-30.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aeterna Zentaris Inc. (AEZS) Business Model
About Aeterna Zentaris Inc.
What They Do
Develops biopharmaceutical therapeutics and diagnostic tests.
Business Model
The company generates revenue through the development and commercialization of its therapeutics and diagnostic products, including Macrilen for growth hormone deficiency. It collaborates with various partners and institutions for research and distribution, thus expanding its market reach and potential revenue streams.
Additional Information
Aeterna Zentaris has a diverse pipeline with products in different stages of development, including therapies for chronic hypoparathyroidism and amyotrophic lateral sclerosis. The company operates internationally, with a presence in multiple countries, enhancing its growth potential in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
Country
Canada
IPO Year
2000
Website
www.zentaris.comAeterna Zentaris Inc. (AEZS) Latest News & Analysis
Latest News
Quick Summary
COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) announced its name change effective August 6, 2024, focusing on biopharmaceuticals and diagnostics in healthcare and cosmetics.
Why It Matters
The rebranding to COSCIENS Biopharma Inc. signals a strategic shift, potentially affecting investor perception, market positioning, and future growth prospects in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aeterna Zentaris Inc. held its virtual annual general and special meeting on July 16, 2024, to discuss voting results on various business items.
Why It Matters
Voting results from Aeterna's annual meeting may indicate shareholder confidence and influence future strategic decisions, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) completed its Phase 3 study on macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency, with results expected in Q3 2024.
Why It Matters
The upcoming top-line data release in Q3 2024 from Aeterna Zentaris could significantly influence stock prices, reflecting investor sentiment on the potential success of macimorelin for CGHD.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ademi LLP is investigating Aeterna (Nasdaq: AEZS) for potential fiduciary duty breaches related to its transaction with Ceapro. Investors may want to monitor this situation.
Why It Matters
The investigation into Aeterna for potential fiduciary breaches may indicate legal risks and impact stock performance, raising concerns about management practices and shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aeterna Zentaris Inc. and Ceapro Inc. have successfully completed an all-stock merger, marking a significant consolidation in the biopharmaceutical sector.
Why It Matters
The merger of Aeterna Zentaris and Ceapro creates a larger entity, potentially enhancing market reach, research capabilities, and investor confidence, impacting stock performance and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
2 years ago
Quick Summary
Aeterna Zentaris Inc. is seeking a court order to extend the deadline for its annual shareholder meeting to July 31, 2024. A hearing is scheduled for June 3, 2024.
Why It Matters
Aeterna's application to extend its annual meeting raises concerns about governance and transparency, potentially impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AEZS Stock
What is Aeterna Zentaris Inc.'s (AEZS) stock forecast for 2027?
Analyst forecasts for Aeterna Zentaris Inc. (AEZS) are not currently available. The stock is trading at $3.73.
Is AEZS stock a good investment in 2027?
According to current analyst ratings, AEZS has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AEZS stock?
Price predictions from Wall Street analysts for AEZS are not currently available. The stock is trading at $3.73.
What is Aeterna Zentaris Inc.'s business model?
The company generates revenue through the development and commercialization of its therapeutics and diagnostic products, including Macrilen for growth hormone deficiency. It collaborates with various partners and institutions for research and distribution, thus expanding its market reach and potential revenue streams.
What is the highest forecasted price for AEZS Aeterna Zentaris Inc.?
Price targets from Wall Street analysts for AEZS are not currently available. The stock is trading at $3.73.
What is the lowest forecasted price for AEZS Aeterna Zentaris Inc.?
Price targets from Wall Street analysts for AEZS are not currently available. The stock is trading at $3.73.
What is the overall AEZS consensus from analysts for Aeterna Zentaris Inc.?
The overall analyst consensus for AEZS is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are AEZS stock price projections?
Stock price projections, including those for Aeterna Zentaris Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2026 12:22 AM UTC